{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:37:36Z","timestamp":1777055856595,"version":"3.51.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69621-8","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:45:25Z","timestamp":1771238725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2+ solid and hematologic cancers"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0586-4073","authenticated-orcid":false,"given":"Yufei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6141-0068","authenticated-orcid":false,"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-0140","authenticated-orcid":false,"given":"Yabo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6001-1077","authenticated-orcid":false,"given":"Miao","family":"Xian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0077-0040","authenticated-orcid":false,"given":"Yong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nestor F.","family":"Esnaola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-3398","authenticated-orcid":false,"given":"Qing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"69621_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"69621_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"69621_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"69621_CR4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"69621_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med. 28, 735\u2013742 (2022).","journal-title":"Nat. Med."},{"key":"69621_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"69621_CR7","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N., Maus, M. V. & Hinrichs, C. S. CAR T cells and T-Cell therapies for cancer: a translational science review. JAMA 332, 1924\u20131935 (2024).","journal-title":"JAMA"},{"key":"69621_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"69621_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn9857","volume":"10","author":"P Erler","year":"2024","unstructured":"Erler, P. et al. Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer. Sci. Adv. 10, eadn9857 (2024).","journal-title":"Sci. Adv."},{"key":"69621_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","volume":"8","author":"SA Batra","year":"2020","unstructured":"Batra, S. A. et al. Glypican-3\u2013specific CAR T cells coexpressing IL15 and IL21 have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol. Res. 8, 309\u2013320 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"69621_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"69621_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 1\u201311 (2021).","journal-title":"Blood Cancer J."},{"key":"69621_CR13","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1038\/sj.onc.1207892","volume":"23","author":"A Niida","year":"2004","unstructured":"Niida, A. et al. DKK1, a negative regulator of Wnt signaling, is a target of the \u03b2-catenin\/TCF pathway. Oncogene 23, 8520\u20138526 (2004).","journal-title":"Oncogene"},{"key":"69621_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.devcel.2008.04.015","volume":"15","author":"H Yamamoto","year":"2008","unstructured":"Yamamoto, H., Sakane, H., Yamamoto, H., Michiue, T. & Kikuchi, A. Wnt3a and Dkk1 regulate distinct internalization pathways of LRP6 to tune the activation of \u03b2-Catenin Signaling. Dev. Cell 15, 37\u201348 (2008).","journal-title":"Dev. Cell"},{"key":"69621_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.devcel.2006.07.003","volume":"11","author":"H Yamamoto","year":"2006","unstructured":"Yamamoto, H., Komekado, H. & Kikuchi, A. Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of \u03b2-catenin. Dev. Cell 11, 213\u2013223 (2006).","journal-title":"Dev. Cell"},{"key":"69621_CR16","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1182\/blood.V106.11.3467.3467","volume":"106","author":"Q Yi","year":"2005","unstructured":"Yi, Q. et al. DKK-1 is a widely expressed, potent tumor-associated antigen in multiple myeloma recognized by cytotoxic T lymphocytes. Blood 106, 3467 (2005).","journal-title":"Blood"},{"key":"69621_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cca.2018.11.023","volume":"488","author":"E Igbinigie","year":"2019","unstructured":"Igbinigie, E., Guo, F., Jiang, S.-W., Kelley, C. & Li, J. Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. Clin. Chim. Acta Int. J. Clin. Chem. 488, 226\u2013234 (2019).","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"69621_CR18","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1158\/0008-5472.CAN-06-3369","volume":"67","author":"T Yamabuki","year":"2007","unstructured":"Yamabuki, T. et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 67, 2517\u20132525 (2007).","journal-title":"Cancer Res."},{"key":"69621_CR19","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/sj.bjc.6603959","volume":"97","author":"N Voorzanger-Rousselot","year":"2007","unstructured":"Voorzanger-Rousselot, N. et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br. J. Cancer 97, 964\u2013970 (2007).","journal-title":"Br. J. Cancer"},{"key":"69621_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abb5727","volume":"13","author":"J Niu","year":"2020","unstructured":"Niu, J. et al. EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3. Sci. Signal. 13, eabb5727 (2020).","journal-title":"Sci. Signal."},{"key":"69621_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1182\/blood-2008-03-145169","volume":"113","author":"JJ Pinzone","year":"2009","unstructured":"Pinzone, J. J. et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113, 517\u2013525 (2009).","journal-title":"Blood"},{"key":"69621_CR22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO-24-01619","volume":"43","author":"T Shi","year":"2025","unstructured":"Shi, T. & Wei, J. Targeting DKK1 to remodel the tumor microenvironment and enhance immune checkpoint blockade therapy. J. Clin. Oncol. 43, 350\u2013353 (2025).","journal-title":"J. Clin. Oncol."},{"key":"69621_CR23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1084\/jem.20150950","volume":"213","author":"L D\u2019Amico","year":"2016","unstructured":"D\u2019Amico, L. et al. Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer.  J. Exp. Med. 213, 827\u2013840 (2016).","journal-title":"J. Exp. Med."},{"key":"69621_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4161\/onci.19655","volume":"1","author":"J Qian","year":"2012","unstructured":"Qian, J. & Yi, Q. DKK1 as a novel target for myeloma immunotherapy. OncoImmunology 1, 756\u2013758 (2012).","journal-title":"OncoImmunology"},{"key":"69621_CR25","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/blood-2007-03-082529","volume":"110","author":"J Qian","year":"2007","unstructured":"Qian, J. et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110, 1587\u20131594 (2007).","journal-title":"Blood"},{"key":"69621_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/PPO.0b013e3181c51f0d","volume":"15","author":"Q Yi","year":"2009","unstructured":"Yi, Q. Novel immunotherapies. Cancer J. 15, 502 (2009).","journal-title":"Cancer J."},{"key":"69621_CR27","doi-asserted-by":"publisher","first-page":"e2338612","DOI":"10.1001\/jamanetworkopen.2023.38612","volume":"6","author":"T Olivier","year":"2023","unstructured":"Olivier, T., Haslam, A., Tuia, J. & Prasad, V. Eligibility for human leukocyte antigen\u2013based therapeutics by race and ethnicity. JAMA Netw. Open 6, e2338612 (2023).","journal-title":"JAMA Netw. Open"},{"key":"69621_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008145","volume":"12","author":"J Qian","year":"2024","unstructured":"Qian, J. et al. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers. J. Immunother. cancer 12, e008145 (2024).","journal-title":"J. Immunother. cancer"},{"key":"69621_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/gcc.20668","volume":"48","author":"L Agnelli","year":"2009","unstructured":"Agnelli, L. et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 48, 603\u2013614 (2009).","journal-title":"Genes Chromosomes Cancer"},{"key":"69621_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ng1532","volume":"37","author":"K Basso","year":"2005","unstructured":"Basso, K. et al. Reverse engineering of regulatory networks in human B cells. Nat. Genet. 37, 382\u2013390 (2005).","journal-title":"Nat. Genet."},{"key":"69621_CR31","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach, T. et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28, 2529\u20132537 (2010).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"69621_CR32","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013W560 (2019).","journal-title":"Nucleic Acids Res."},{"key":"69621_CR33","first-page":"1","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff, J. et al. Pancreatic cancer. Nat. Rev. Dis. Prim. 2, 1\u201322 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"69621_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccr.2009.07.016","volume":"16","author":"H Pei","year":"2009","unstructured":"Pei, H. et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16, 259\u2013266 (2009).","journal-title":"Cancer Cell"},{"key":"69621_CR35","doi-asserted-by":"publisher","first-page":"e1651","DOI":"10.1371\/journal.pone.0001651","volume":"3","author":"MT Landi","year":"2008","unstructured":"Landi, M. T. et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 3, e1651 (2008).","journal-title":"PLoS ONE"},{"key":"69621_CR36","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352 (2012).","journal-title":"Nature"},{"key":"69621_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B","volume":"1","author":"T Otsuki","year":"2000","unstructured":"Otsuki, T. et al. Genetic and biological characterization of human myeloma cell lines: An overwiew of the lines established at Kawasaki Medical School. Gene Funct. Dis. 1, 48\u201356 (2000).","journal-title":"Gene Funct. Dis."},{"key":"69621_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.omto.2020.05.009","volume":"17","author":"C-Y Yang","year":"2020","unstructured":"Yang, C.-Y. et al. Engineering chimeric antigen receptor T cells against immune checkpoint inhibitors PD-1\/PD-L1 for treating pancreatic cancer. Mol. Ther. Oncolytics 17, 571\u2013585 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"69621_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo, M. et al. Patient derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998\u20131013 (2014).","journal-title":"Cancer Discov."},{"key":"69621_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","volume":"35","author":"H Du","year":"2019","unstructured":"Du, H. et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell 35, 221\u2013237.e228 (2019).","journal-title":"Cancer Cell"},{"key":"69621_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002555","volume":"9","author":"DG Tantalo","year":"2021","unstructured":"Tantalo, D. G. et al. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. J. Immunother. Cancer 9, e002555 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"69621_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","volume":"16","author":"Y Bulliard","year":"2023","unstructured":"Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. & Tsimberidou, A. M. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J. Hematol. Oncol. 16, 108 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"69621_CR43","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh, D. et al. IL15 enhances CAR-T-cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol. Res. 7, 759\u2013772 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"69621_CR44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150807","volume":"132","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli, S. et al. CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J. Clin. Investig. 132, e150807 (2022).","journal-title":"J. Clin. Investig."},{"key":"69621_CR45","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"69621_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1365-2249.2012.04642.x","volume":"170","author":"S Hong","year":"2012","unstructured":"Hong, S. et al. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin. Exp. Immunol. 170, 167\u2013177 (2012).","journal-title":"Clin. Exp. Immunol."},{"key":"69621_CR47","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1034\/j.1600-065X.2003.00035.x","volume":"194","author":"K Vanderkerken","year":"2003","unstructured":"Vanderkerken, K., Asosingh, K., Croucher, P. & Van Camp, B. Multiple myeloma biology: lessons from the 5TMM models. Immunol. Rev. 194, 196\u2013206 (2003).","journal-title":"Immunol. Rev."},{"key":"69621_CR48","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1161\/ATVBAHA.109.189761","volume":"29","author":"T Ueland","year":"2009","unstructured":"Ueland, T. et al. Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb. Vasc. Biol. 29, 1228\u20131234 (2009).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"69621_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple negative breast cancer: Pitfalls and progress. npj Breast Cancer 8, 1\u201310 (2022).","journal-title":"npj Breast Cancer"},{"key":"69621_CR50","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/13543784.2020.1769065","volume":"29","author":"JA Wall","year":"2020","unstructured":"Wall, J. A., Klempner, S. J. & Arend, R. C. The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin. Investig. Drugs 29, 639\u2013644 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"69621_CR51","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"69621_CR52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu, B., Jiang, T. & Liu, D. BCMA-targeted immunotherapy for multiple myeloma. J. Hematol. Oncol. 13, 125 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"69621_CR53","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","volume":"127","author":"JH Park","year":"2016","unstructured":"Park, J. H., Geyer, M. B. & Brentjens, R. J. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127, 3312\u20133320 (2016).","journal-title":"Blood"},{"key":"69621_CR54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41417-021-00295-8","volume":"29","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb. Cancer Gene Ther. 29, 167\u2013177 (2022).","journal-title":"Cancer Gene Ther."},{"key":"69621_CR55","doi-asserted-by":"publisher","first-page":"1385571","DOI":"10.3389\/fimmu.2024.1385571","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu, Z. et al. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front. Immunol. 15, 1385571 (2024).","journal-title":"Front. Immunol."},{"key":"69621_CR56","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41435-024-00275-6","volume":"25","author":"X Li","year":"2024","unstructured":"Li, X., Zhao, L., Li, W., Gao, P. & Zhang, N. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo. Genes Immun. 25, 201\u2013208 (2024).","journal-title":"Genes Immun."},{"key":"69621_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007927","volume":"12","author":"GP Botta","year":"2024","unstructured":"Botta, G. P. et al. Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells. J. Immunother. Cancer 12, e007927 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"69621_CR58","doi-asserted-by":"crossref","unstructured":"Uslu U., June C. H. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nature Biotechnol. 43, 506\u2013515 (2024).","DOI":"10.1038\/s41587-024-02446-2"},{"key":"69621_CR59","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han, X., Wang, Y., Wei, J. & Han, W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J. Hematol. Oncol. 12, 128 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"69621_CR60","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi, K. et al. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904\u2013918 (2021).","journal-title":"Nat. Cancer"},{"key":"69621_CR61","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","volume":"23","author":"T Gebhardt","year":"2023","unstructured":"Gebhardt, T., Park, S. L. & Parish, I. A. Stem-like exhausted and memory CD8+ T cells in cancer. Nat. Rev. Cancer 23, 780\u2013798 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"69621_CR62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18\u201327 (2017).","journal-title":"Nat. Med."},{"key":"69621_CR63","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"69621_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008566","volume":"12","author":"TB Shabaneh","year":"2024","unstructured":"Shabaneh, T. B. et al. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity. J. Immunother. Cancer 12, e008566 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"69621_CR65","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","volume":"36","author":"ML Olson","year":"2022","unstructured":"Olson, M. L. et al. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia 36, 1943\u20131946 (2022).","journal-title":"Leukemia"},{"key":"69621_CR66","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s42003-022-04368-8","volume":"5","author":"NP Jaschke","year":"2022","unstructured":"Jaschke, N. P. et al. Dickkopf1 fuels inflammatory cytokine responses. Commun. Biol. 5, 1391 (2022).","journal-title":"Commun. Biol."},{"key":"69621_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19672-2","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nat. Commun. 11, 5902 (2020).","journal-title":"Nat. Commun."},{"key":"69621_CR68","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","volume":"33","author":"X Ma","year":"2021","unstructured":"Ma, X. et al. CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability. Cell Metab. 33, 1001\u20131012.e1005 (2021).","journal-title":"Cell Metab."},{"key":"69621_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44873-4","volume":"15","author":"F Sun","year":"2024","unstructured":"Sun, F. et al. Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth. Nat. Commun. 15, 615 (2024).","journal-title":"Nat. Commun."},{"key":"69621_CR70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma, X. et al. Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell Metab. 30, 143\u2013156.e145 (2019).","journal-title":"Cell Metab."},{"key":"69621_CR71","doi-asserted-by":"publisher","first-page":"8808","DOI":"10.1158\/1078-0432.CCR-05-1553","volume":"11","author":"J Qian","year":"2005","unstructured":"Qian, J. et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 11, 8808\u20138815 (2005).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"69621_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ijc.28958","volume":"136","author":"B Hong","year":"2015","unstructured":"Hong, B. et al. p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int. J. Cancer 136, 34\u201343 (2015).","journal-title":"Int. J. Cancer"},{"key":"69621_CR73","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/leu.2013.177","volume":"28","author":"I Sakamaki","year":"2014","unstructured":"Sakamaki, I. et al. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 28, 329\u2013337 (2014).","journal-title":"Leukemia"},{"key":"69621_CR74","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/gutjnl-2016-313133","volume":"67","author":"ES Knudsen","year":"2018","unstructured":"Knudsen, E. S. et al. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut 67, 508\u2013520 (2018).","journal-title":"Gut"},{"key":"69621_CR75","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-16-2703","volume":"23","author":"L Zhang","year":"2017","unstructured":"Zhang, L. et al. B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin. Cancer Res. 23, 4212\u20134223 (2017).","journal-title":"Clin. Cancer Res."},{"key":"69621_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50073-x","volume":"15","author":"M Xian","year":"2024","unstructured":"Xian, M. et al. Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis. Nat. Commun. 15, 5767 (2024).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69621-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69621-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69621-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:04:08Z","timestamp":1774541048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69621-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69621"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69621-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.Q., W.X., and Q.Y. are inventors on patents in the field of DKK1-A2 targeted Therapies. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2818"}}